The stakes were high: This was the final phase — phase 3 — of MAPS’s study aiming to convince the FDA to approve MDMA-assisted therapy for PTSD. Doblin knew that if the participants didn’t see improvement, it might mar his research results. Still, he refused to heed the warning.
“I said: Bessel, in our phase 2, we did work with people with complex PTSD, with childhood sexual abuse, with all sorts of poor attachment styles — and they seemed to get better! So we will continue to include those,” Doblin recalled.
Originally appearing here (Archived)